Riches, Simon http://orcid.org/0000-0002-1427-5561
Kaleva, Ina http://orcid.org/0000-0003-4303-924X
Nicholson, Sarah L. http://orcid.org/0000-0001-5153-7738
Payne-Gill, James http://orcid.org/0000-0003-1802-4695
Steer, Natalie http://orcid.org/0000-0002-0149-4298
Azevedo, Lisa http://orcid.org/0000-0002-9148-7496
Vasile, Ruxandra http://orcid.org/0000-0002-8270-3580
Rumball, Freya http://orcid.org/0000-0002-7099-6523
Fisher, Helen L. http://orcid.org/0000-0003-4174-2126
Veling, Wim http://orcid.org/0000-0002-1364-9779
Valmaggia, Lucia http://orcid.org/0000-0001-6099-8464
Funding for this research was provided by:
Health Innovation Network
Article History
Received: 28 November 2023
Revised: 26 January 2024
Accepted: 31 January 2024
First Online: 28 March 2024
Declarations
:
: The study gained ethical approval from King’s College London (HR-19/20–19650).
: All individual participants included in the study provided informed consent for their participation.
: All individual participants included in the study provided informed consent for publication of their data.
: Wim Veling is the cofounder of VRelax BV, the company that has developed the VR application in collaboration with University Medical Center Groningen, and holds shares in VRelax BV. There are no other conflicts of interest.
: The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, Department of Health, the ESRC, or King’s College London.